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The prognosis of segmental glomerulonephritis in systemic lupus
erythematosus. Severe segmental glomerulonephritis (Seg GN) ( 50%
involvethent) in systemic lupus erythematosus (SLE) is classified as
diffuse ON (DPGN) in the WHO classification. We tested the validity of
the assumption that severe Seg ON and DPGN have the same prognosis
by determining the proportion of glomeruli involved by active segmen-
tal inflammation in a series of 127 patients and by comparing the
prognosis in vatious categories of Seg ON with patients with DPGN. In
Seg GN we found mild involvement (Ito 19%) in 19 patients, moderate
involvement (20 to 49%) in 9 patients and severe involvement ( 50%)
in 17 patients. There were 28 cases of DPGN. The actuarial five—year
survival of patients with mild and moderate Seg GN was 82%. The
survival of patients with severe Seg GN and DPUN were 59 and 53%,
respectively. The incidence of adverse outcomes, including death,
end—stage kidney disease, and deterioration of renal function was
similar in patients with severe Seg ON and DPGN, and greater than in
patients with mild and moderate Seg GN. Although there was a trend
associating increasing glomerular involvement with elevated urinary
protein excretion and serum creatinine and decreased serum C3 and C4,
the differences were not significant. Cumulative prednisone dose and
prednisone given in the first and second years following biopsy were not
different in the various categories of Seg GN and DPGN, suggesting
that differences in outcome were not related to the amount of predni-
sone therapy. We conclude that the prognosis in SLE Seg ON is a
function of the proportionality of glomerular involvement, and in severe
Seg ON the five year survival and clinical outcome is similar to that of
DPGN. In SLE GN involvement of 50% or more of the glomeruli in a
renal biopsy b active segmental lesions identifies a group of patients
with a poor prognosis.
The nature of the degree of involvement of the renal glomer-
ulus is a reliable prognostic sign in systemic lupus erythem-
atosus [1—3]. This may be because the glomerular pathology
accurately reflects the severity of the systemic disease process.
An additional consideration is the fact that morbidity and
mortality may result from therapeutic measures which are more
extreme in patients with more severe active glomerular and
systemic involvement. In order to clarify certain controversial
aspects of the histologic classification of glomerular abnormal-
ities in SLE, the World Health Organization published a
schema which was designed to create a more uniform approach
to the interpretation of renal biopsy material [4]. An important
feature of the WHO classification was to provide a definition of
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the glomerular lesion with the most serious prognosis, diffuse
proliferative glomerulonephritis (DPGN). Despite many posi-
tive features of the WHO classification, the definition of DPGN
and its relationship to the other major form of SLE proliferative
glomerulonephritis (GN), segmental GN, remain ambiguous.
Renal biopsies from SLE patients with segmental ON present a
spectrum of qualitatively similar lesions which differ widely in
the extent of glomerular involvement. In the WHO classifica-
tion, the category of DPGN is comprised of biopsies with
diffuse global involvement and biopsies in which the majority of
the glomeruli have a segmental lesion. Implicit in this notion of
classification, then, is the assumption that the inflammatory
disease process is the same in both instances. On the basis of
clinical outcome and morphologic features, it is not clear that
this assumption is correct. Because the WHO classification
does not address the issue of the relationship between severe
segmental GN ( 50 percent involvement) and diffuse global
involvement, we have quantitated the extent of segmental
involvement in order to determine the prognostic significance of
this lesion. These studies will test the validity of including
biopsies with severe segmental GN in the category of DPGN.
Methods
Patients
One hundred and twenty—seven patients biopsied at
Rush—Presbyterian—St. Luke's Medical Center, Chicago, Illi-
nois and William Beaumont Hospital, Royal Oaks, Michigan,
between August, 1968 and April, 1984 formed the cohort from
which patients were drawn. All patients fulfilled the clinical
criteria of the American Rheumatism Association for SLE [5].
Biopsies were classified according to the proposal of the Inter-
national Study of Kidney Disease in Children, as adopted by the
World Health Organization [4]. The diagnosis of segmental and
diffuse GN were modified to analyze the significance of the
extent of segmental histologic activity. The histologic interpre-
tation was carried out by one of us (MMS) without knowledge
of the clinical status of the patient or the clinical outcome.
Morphologic classification
In the WHO classification segmental GN is characterized by
active lesions (Category lila), active and sclerotic lesions
combined (Category IIIb), and sclerotic lesions only (Category
IIIc). The distribution of glomerular lesions is primarily deter-
mined by light microscopy, but the WHO Classification utilizes
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fluorescence and ultrastructural findings in the determination of
activity and the localization of immune aggregates. The distri-
bution of the lesion within the glomerulus and the active nature
of the inflammatory process are illustrated in Figure 1. In the
present study the proportion of glomeruli with active segmental
lesions (Fig. IA) was determined by dividing the number of
glomeruli with histologic activity by the total glomeruli. The
total glomeruli included uninvolved glomeruli and glomeruli
with segmental activity and scars. Segmental scars could coex-
ist in the same glomerulus or in other glomeruli in a biopsy with
active lesions. However, segmental scars were not counted as
active lesions, and glomeruli which were more than 80 percent
replaced by scars were not included in the total glomerular
count. Biopsies which contained only segmental scars (Cate-
gory Ilic) were excluded from analysis. These definitions
emphasize glomerular lesions which are presumed to reflect the
patient's current renal activity. By excluding segmental scars as
active lesions and global glomerular sclerosis from the total
glomerular count, we avoided lesions of unknown prognostic
significance and uncertain therapeutic implication. Histological
signs of activity included necrosis, disruption of capillary walls,
infiltration by neutrophils, karyorrhexis, hematoxyphil bodies,
cellular crescents, wire—loops, hyaline thrombi, fibrin thrombi,
and segmental fibrin deposition. The active segmental lesions
were divided into three groups based on the proportion of
glomeruli involved: mild (1 to 19%), moderate (20 to 49%), and
severe (equal to or greater than 50%). Since the WHO classifi-
cation includes biopsies with greater than 50 percent involve-
ment with DPGN (category IV), our category of segmental GN
with greater than 50 percent involvement was comprised of
cases which would have been classified as DPGN.
DPGN was diagnosed when more than 80 percent of the
glomeruli had severe cellular proliferation and infiltration in a
global mesangial, endocapillary (Fig. 1B) or mesangiocapillary
(Fig. 1C) pattern and/or when prominent, extensive subendo-
thelial deposits (wire—loops) were seen by light microscopy. In
addition to removing biopsies with widespread ( 50 percent)
segmental activity from this category, we were careful to
exclude cases of diffuse membranous ON which had associated
severe segmental or diffuse proliferative GN. The latter lesions
are classified with membranous GN (category V) in the WHO
classification.
Pathology techniques
Renal tissue, obtained by percutaneous or open biopsy, was
divided for study by light, immunofluorescence, and electron
microscopy. For light microscopy tissue was fixed in
Duboscq—Brasil solution, embedded in paraffin, and 2 to 4
micron sections were stained with hematoxylin and eosin,
periodic acid Schiff, Jones' Methenaniine silver periodic acid
Schiff, and Masson's trichrome. Immunofluorescence and elec-
tron microscopy were performed by previously published tech-
niques [6].
Clinical and laboratory data
The serum creatinine, 24-hour urinary protein excretion,
serum C3 and C4 and the patient's age was recorded at the time
of the renal biopsy. The length of follow-up was defined as the
time from the initial biopsy to the last clinic visit or the last
recorded serum creatinine. The final available serum creatinine
Fig. 1. Distribution of proliferative lesions in SLE GN. A. Segmental
lesion with characteristic sparring of the uninvolved portion of the
glomerulus. This feature allows identification of this lesion even when
virtually every glomerulus is involved. B. Diffuse lesion, endocapillary
proliferation. There is total involvement of the glomerulus, and more
than 80% of the glomeruli in the biopsy are involved. C. Diffuse lesion,
membranoproliferative pattern. This variant is characterized by diffuse
mesangial proliferation, and widespread remodeling of the glomerular
capillary wall (arrows) caused by reaction to and organization of large
subendothelial deposits. A and B, Hematoxylin and eosin. C, Periodic
acid Schiff. (A, B, C x250).
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moderate segmental glomerulonephritis had survivals of 80 and
86 percent, respectively, which is similar to that reported for
mesangial SLE GN (WHO category II). When the patients with
mild and moderate Seg GN were combined, their actuarial
survival at five years was 82%, which is in contrast with the
53% five—year survival experienced by patients wtih DPGN.
Patients with severe segmental GN had a survival intermediate
between that of the patients with less extensive segmental
lesions and DPGN. However, the survival was not significantly
different between severe segmental ON and DPGN, and after
five years, the survival curve for severe segmental GN ap-
proached that of DPGN.
Examination of discrete outcomes (Table 1) showed the same
trend. Patients with mild and moderate segmental glomerulone-
phritis had the lowest incidence of unfavorable outcomes.
Patients with severe segmental and DPGN had a similar and
considerably higher incidence of renal death, end—stage renal
disease and non-renal death.
Clinical and laboratory paramenters
and 24-hour urinary protein excretion were recorded. Addi-
tional clinical information included the total dose of prednisone
(calculated from clinic records), the duration of therapy (deter-
mined from the onset of therapy which frequently antedated the
renal biopsy), and the amount of prednisone given in the first
year, and the first plus the second year after the renal biopsy.
Declining renal function was defined as a 40 percent increase iP
serum creatinine, and renal improvement required a decrease in
serum creatinine of 0.2 mg/dl.
Statistical analysis
The patient survival in each histopathologic category was
calculated by life—table analysis. Unfavorable outcomes were
renal death, non-renal death, and chronic renal failure (serum
creatinine  4.0 mg/dl). Analysis of variance was used to test
for differences between groups. Multiple comparisons were
performed using the Tukey HSD procedure. Values are given as
mean standard deviation.
Results
Histopathologic classification
Forty—five out of 127 SLE renal biopsies fulfilled our criteria
for "active" segmental ON. In the 19 patients with mild
involvement (1 to 19%) 9 5% (mean SD) of the glomeruli
had active segmental lesions. Moderate involvement (20 to
49%) was seen in nine patients who had 36 9% of their
glomeruli involved. Severe involvement ( 50%) was seen in 17
patients who had active segmental lesions in 68 18% of their
glomeruli. All of these 45 patients had active lesions, and
therefore, they belonged in WHO categories lila or Ilib.
Twenty-eight biopsies fulfilled our criteria for category IV
(diffuse glomerulonephritis),
Outcome
The survival curves generated from the life—table analysis are
presented in Figure 2, and the discrete clinical outcomes for
each histopathologic category are listed in Table 1. A propor-
tional relationship exists between the extent of segmental
inflammation and the five year survival. Patients with mild and
Selected clinical and laboratory values for the subcategories
of segmental and diffuse glomerulonephritis are listed in Table
2, and the details of prednisone therapy are listed in Table 3.
Although there is a trend which suggests that degree of glomer-
ular inflammation is proportional to the serum creatinine and
24-hour protein excretion and inversely related to the serum C3,
there was significant overlap in individual cases, and most of
the parameters did not differ significantly.
The total dose of prednisone was similar among the different
biopsy categories, and when the total dose was factored by the
time over which the drug was prescribed, it appeared as if the
more severe inflammatory lesions were given more prednisone
per month. However, when the prednisone dose was calculated
for the critical years after the biopsy, there was no significant
difference in prednisone dosage in the first year or in the first
and second year combined. Differences in cumulative predni-
sone dose did not appear to explain clinical outcomes encoun-
tered during this study. Neither the higher death rate found
among severe Seg ON and DPGN patients nor the higher
end—stage renal failure rate noted in these same histogic cate-
gories could be explained on the basis of over—treatment or
under—treatment, respectively.
Discussion
The significance of the focal and segmental lesion of SLE
glomerulonephritis, while controversial, is of considerable clin-
ical importance. Early attempts to classify lupus nephritis led to
the observation that the patients with DPGN had a poor
prognosis, while those with lesser glomerular changes, referred
to as focal glomerulonephritis, responded more favorably to
therapy and had a lower mortality rate [1—3]. As more experi-
ence accumulated, it has become clear that the category of focal
glomerulonephritis (segmental GN in the WHO classification) is
comprised of a spectrum of immune—mediated inflammatory
lesions, and that the variable course of the renal and systemic
disease may be related to the nature and the extent of the
histologic abnormality [7, 8]. In contrast to other observers who
have found a relatively good prognosis in patients with segmen-
tal glomerulonephritis, several recent studies have reported
similar outcomes for SLE patients with Seg ON and DPGN
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Fig. 2. Cumulative survival for patients with the various subcategories
of segmental GN and DPGN. Symbols are: (—) mild and moderate
segmental ON; ( ) severe segmental GN; and (- - -) DPON.
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Table 1. Outcome of lupus nephritis at five years
Percent Percent Percent
Percent of patients with
Decline in Renal
Biopsy category # Patients survival RD/CRD NRD renal function improvement
Segmental
GN, mild (Ito 19%) 19 84(16) 5(1) 11(2) 21(4) 42(8)
Segmental
GN, moderate (20 to 49%) 9 89(8) 0 (0) 11(1) 11(1) 33 (3)
Segmental
GN, severe (50%) 17 65(11) 23(4) 12(2) 35(6) 29(5)
Diffuse GN 28 61(17) 25 (7) 14 (4) 18 (5) 25 (7)
All 73 71(52) 16 (12) 13 (9) 23(16) 32 (23)
Abbreviations are: (N) number of patients: survival, includes all patients who were alive when last seen and did not develop chronic renal failure;
RD, (Renal Death) implies death directly attributable to renal disease; NRD. (Nonrenal Death) death due to non-renal systemic disease or a
complication of therapy; ECRD. (End Chronic Renal Disease) serum creatinine 4.0 mg/dl; Decline in renal function, An increase in serum
creatinine 40% (CRD included); and Renal improvement, a decrease in serum creatinine mg/dl.
a Three additional patients who presented with elevated serum creatinines progressed to ECRD without experiencing a 40% decline in renal
function.
Table 2. Laboratory data by biopsy category
Creatinine Proteinuria Creatinine Proteinuria
Age at initial initial C3 initial C4 initial final final
Biopsy biopsy mgldl SD g/24 hr SD mgldl SD mg/dl ca Follow-up mgldl SD g/14 hr SD
category years SD (<J/)a (<O.25)a (>80)a (>20)a months SD (<JJ)a (<025)a
I) Seg GN, 31 13 1.3 0.8 1.3 1.7 75 36 21 18 48 36 1.1 0.7 0.3 0.5
mild (19) (19) (16) (18) (17) (18) (18) (7)
2) SegGN, 32 10 1.5 1.2 1.5 1.3 66 23 II 6 54 51 1.1 0.6 5.1 5.6
moderate (9) (9) (8) (9) (8) (7) (7) (4)
3) Seg GN. 30 7 1.9 1.5 2.5 2.5 61 29 22 17 41 27 3.1 4.1 1.6 2.0
severe (17) (17) (IS) (16) (15) (11) (16) (II)
4) Diffuse 29 12 2.2 2.1 4.4 3.6 67 44 13 10 29 29 3.3 3,8 3.9 2.3
GN (28) (28) (28) (27) (27) (24) (26) (12)
All 30 II
(73)
NSh
1.8 1.6
(73)
NS
2.9 3.1
(67)
4> 1
68 36
(70)
NS
NS
17 15
(67)
NS
40 34
(60)
NS
2.4 3.3
(67)
NS
2.5 3
(34)
4> 1
2>1
a Normal values
b No two values significantly different at the 0.050 level
[9—12]. Appel eta! [9] observed that patients with segmental GN
who had less than 50% of glomeruli involved had an identical 70
percent, four year rate of survival as occurred in patients with
DPGN. By classifying severe segmental GN ( 50%) and
diffuse global GN together as DPGN, the authors of the WHO
Classification imply that these two lesions have the same
natural history, but when the WHO Classification was pro-
posed, this hypothesis was untested. The present study reveals
that the overall prognosis in patients with segmental GN is
proportional to the extent of glomerular involvement with
active immune and inflammatory lesions. Patients with mild
(less than 20%) and moderate (20 to 49%) involvement clearly
had better cumulative survival rates than those with more
extensive glomerular involvement. Those patients designated
severe segmental glomerulonephritis ( 50% involvement) had
an intermediate four year prognosis between patients who had
segmental GN with less than 50% involvement and those with
DPGN.
Taken literally, the intermediate prognosis of severe segmen-
tal GN between the less—extensive segmental lesions and
DPGN means that prognosis is a direct function of the extent of
glomerular involvement. The high incidence of adverse out-
comes among patients with severe segmental GN further sup-
ports the contention that they share the same prognosis as
DPGN. Despite considerable support for this interpretation,
others have contested not only the relevance of histological
activity [13, 14] to prognosis but the renal biopsy itself [15, 16].
Before accepting the conclusions of this or any other retrospec-
tive clinico-pathologic study, there are two caveats which the
reader must consider. First, it is assumed that the first renal
biopsy is obtained after the onset of renal involvement in a
patient who has had these abnormalities for a relatively short
period of time. All of our patients were seen in a primary
nephrology practice, and the index biopsy represented either
the first biopsy or the biopsy associated with a concurrent
clinical flare. Since the survival of patients with SLE GN is
significantly improved by therapy, a clinico-pathologic study
may only be valid if the patients are compliant and managed in
a reasonably consistent manner by a limited number of physi-
cians. Over 2/3 of our patients were seen by nephrologists who
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Table 3. Relationship between biopsy category and cummulative prednisone dose
Biopsy category
Prednisone
Total
g SD
Duration of therapy
months SD
Average
gimo SD
First year
g SD
First and second year
g SD
1) Seg GN, mild
2) Seg GN, moderate
3) SegGN, severe
4) Diffuse GN
34 27
(18)
32 28
(9)
46 43
(17)
34 36
(24)
59 34
(18)
86 79
(9)
59 55
(17)
34 31
(24)
0.59 0.35
(18)
0.085 0.78
(9)
0.92 0.55
(17)
1.1 0.50
(24)
11 5
(15)
11 5
(9)
12 5
(14)ii 5
(20)
17 7
(14)
15 6
(5)
20 6
(10)20 5
(15)
All 37 35
(68)
NS
53 49
(68)2>4
0.89 0.55
(68)4>1
11 5
(58)
NS
18 6
(44)
NS
have a consistent therapeutic philosophy, and they were
biopsied because of clinical evidence of renal disease. The
similar amounts of prednisone received by patients in the
different categories (Table 3) supports the relative uniformity of
their therapeutic program. Thus, the biopsy diagnoses we are
reporting represent the current state of disease activity as
expressed in the glomeruli, and if the morphology has been
modified by therapy, treatment has been consistent among the
histological classes.
Our results further imply that the histologic activity seen in
the initial renal biopsy tells us something important about the
biology of SLE in the individual patient. Although transforma-
tions among the histologic categories of SLE GN are well
documented [17], the impact of therapy upon these tendencies
for some patients to manifest different degrees of glomerular
involvement during their course is not clear. It would seem
intuitively to be the case that a patient with a relatively—mild
glomerular lesion who is non-compliant to therapy or not
treated with adequate levels of adrenal steroids may develop a
more advanced lesion, while those patients with severe Seg GN
or DPGN who respond to therapy are assumed to resolve their
glomerular lesions. Although consistency of therapeutic ap-
proach may be important with respect to long term prognosis,
we propose that the initial biopsy findings correlate with prog-
nosis because the degree of glomerular inflammation at the time
of biopsy appears to reflect the overall severity of disease
activity. We do not mean to imply that patients with SLE have
a fixed degree of glomerular involvement throughout their
course irrespective of therapy or other clinically relevant
events. However, our data does appear to justify the assump-
tion of a prognostic implication on the basis of the initial
glomerular histology.
Our results accord with the implications of the World Health
Organization Classification that the clinical outcome of patients
with segmental glomerulonephritis is a function of the propor-
tionality of glomerular involvement. Those individuals with
more than half of their glomeruli involved by an active inflam-
matory lesion, as defined by the WHO Classification, behave
clinically in a manner similar to those with diffuse forms of SLE
glomerulonephritis. Conversely, patients with a lower percent-
age of glomerular involvement have a relatively benign course.
The extent of glomerular involvement in severe segmental and
diffuse glomerulonephritis may recruit non-immunological
mechanisms of glomerular injury which contribute to the poor
prognosis in these groups. Although the WHO Classification
does not distinguish among possible pathogenetic mechanisms,
it does appropriately identify patients with severe segmental
GN as a group of patients at risk who require therapeutic
intervention.
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